MedTrace Logo

Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA

NCT03499678 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2023-12-22

No results posted yet for this study

Summary

A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast and lung cancers, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of lung cancer is urgently needed.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in lung cancer patients.

Conditions

  • Lung Cancer
  • Lung Cancer, Nonsmall Cell
  • Lung Cancer, Small Cell

Sponsors & Collaborators

  • Kazakh Research Institute of Oncology & Radiology

    collaborator OTHER

  • HKGepitherapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-07-19
Completion
2019-07-19

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03499678 on ClinicalTrials.gov